Spectral Medical Inc. announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial. Under the terms of the Company?s Exclusive Distribution Agreement with Baxter International(?Baxter?), at Interim Enrollment, Baxter has the option to make a second milestone payment to Spectral to maintain its PMX exclusive distribution rights. As such, Spectral has formally notified Baxter of reaching its Interim Enrollment target of 90 patients.